Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428783 | 0.97 | P2RY12 (0.47) | P2RY12MEN1POLBKMT2AMAPT | |
| SCHEMBL3217492 | 0.89 | P2RY12 (0.48) | P2RY12MEN1KMT2AMAPTTDP1 | |
| SCHEMBL8179402 | 0.87 | MEN1 (0.47) | P2RY12MEN1POLBKMT2AMAPT | |
| SCHEMBL3222737 | 0.85 | ALDH1A1 (0.52) | P2RY12KMT2AMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL8182970 | 0.83 | MEN1 (0.47) | MEN1POLBKMT2AMAPTTDP1 | |
| SCHEMBL13428793 | 0.83 | L3MBTL1 (0.44) | P2RY12KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL13428784 | 0.80 | MAPT (0.43) | P2RY12MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL13428798 | 0.79 | KDM4E (0.51) | P2RY12MEN1POLBKMT2AL3MBTL1 | |
| SCHEMBL3222922 | 0.77 | PIK3CD (0.48) | MAPTKDM4EALDH1A1 | |
| SCHEMBL13428779 | 0.77 | CYP1A2 (0.47) | P2RY12MEN1POLBKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2099756-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008075757-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | P2RY12 4610/4885MEN1 2025/4885POLB 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.